10-Q: Anixa Biosciences Reports First Quarter 2025 Results, Focuses on Cancer Vaccine and CAR-T Therapeutics Development

Anixa Biosciences reports its financial results for the first quarter of 2025, highlighting its ongoing efforts in developing cancer vaccines and CAR-T therapeutics.

Summary

• Anixa Biosciences reported its financial results for the first quarter ended January 31, 2025.
• The company is focused on developing therapies and vaccines for unmet needs in oncology.
• Key programs include a chimeric endocrine receptor-T cell therapy for ovarian cancer and vaccines against breast and ovarian cancer.
• The company's subsidiary, Certainty Therapeutics, is developing immunotherapy drugs against cancer.
• A Phase 1 clinical trial for the breast cancer vaccine is ongoing, with promising immunological data presented.
• The company anticipates commencing a Phase 2 trial for the breast cancer vaccine in 2025.
• Anixa is collaborating with Cleveland Clinic to develop additional vaccines for other cancers.
• The company had approximately $18.7 million in total current assets as of January 31, 2025, compared to $21.4 million at October 31, 2024.
• Anixa believes its existing cash, cash equivalents, and short-term investments will be sufficient to fund activities for at least the next twelve months.
• The company had no revenue for the three months ended January 31, 2025 and 2024.
• Research and development expenses increased to $1.55 million for the three months ended January 31, 2025, from $1.35 million for the same period in 2024.
• General and administrative expenses decreased to $1.83 million for the three months ended January 31, 2025, from $2.26 million for the same period in 2024.
• The net loss attributable to common shareholders was $3.18 million, or $0.10 per share, for the three months ended January 31, 2025.
• Under the company's at-the-market equity program, as of January 31, 2025, it may sell approximately $97 million of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is making progress in its clinical trials and has sufficient cash to fund operations for the next twelve months. However, it is still in the early stages of development and is not generating revenue.

Positives

• The company is making progress in its clinical trials for the breast cancer vaccine, with promising immunological data.
• The company is expanding its vaccine development efforts through collaboration with Cleveland Clinic.
• The company believes it has sufficient cash to fund operations for at least the next twelve months.
• General and administrative expenses decreased by approximately $426,000 in the three months ended January 31, 2025.

Negatives

• The company had no revenue for the three months ended January 31, 2025.
• The company reported a net loss attributable to common shareholders of $3.18 million for the three months ended January 31, 2025.
• Cash, cash equivalents, and short-term investments decreased approximately $2.7 million during the quarter.

Risks

• The company's success depends on the successful development and commercialization of its therapies and vaccines, which are subject to clinical trial risks and regulatory approvals.
• The company may need to raise additional capital in the future to fund its operations.
• The company faces competition from other biotechnology companies developing cancer therapies and vaccines.
• The company's intellectual property rights may be challenged or invalidated.

Future Outlook

Based on currently available information as of March 11, 2025, the company believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund its activities for at least the next twelve months, and anticipates commencing a Phase 2 trial for the breast cancer vaccine in 2025.

Management Comments

• The company has implemented a business model that conserves funds by collaborating with third parties to develop its technologies.
• The company hopes to achieve a profitable outcome by eventually licensing its technologies to large pharmaceutical companies.

Industry Context

Anixa Biosciences is operating in the competitive biotechnology industry, focusing on cancer vaccines and CAR-T therapeutics, which are areas of significant unmet medical need and ongoing research and development. The company's collaborations with institutions like Cleveland Clinic and Moffitt Cancer Center are common strategies in the biotech industry to leverage expertise and resources.

Comparison to Industry Standards

• Many biotechnology companies in the early stages of clinical development, like Anixa, do not generate revenue and rely on funding through investments, grants, and partnerships.
• Research and development expenses are typical for companies in this sector, as they invest heavily in preclinical and clinical studies.
• Collaborations with academic institutions and research centers are common in the biotech industry to advance research and development efforts.
• Companies like Moderna and BioNTech have successfully developed and commercialized mRNA-based vaccines, demonstrating the potential of vaccine technologies in addressing significant health challenges.
• CAR-T therapy companies like Kite Pharma (acquired by Gilead) and Novartis have achieved regulatory approvals and commercial success with their CAR-T products, highlighting the potential of this therapeutic approach in oncology.

Legal Proceedings

• Other than lawsuits related to the enforcement of our patent rights, we are not a party to any material pending legal proceedings, nor are we aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and financial stability are positive for shareholders.
• Employees: The company's focus on research and development provides opportunities for employees.
• Patients: The company's development of cancer therapies and vaccines has the potential to improve patient outcomes.

Next Steps

• The company is preparing to enroll patients in the 4th dose cohort of the ovarian cancer CAR-T therapy trial.
• The company anticipates commencing a Phase 2 trial for the breast cancer vaccine in 2025.
• The company expects the development of its therapeutics and vaccines to be the primary focus of the Company over the next several quarters.
• The company is working with Cleveland Clinic researchers to discover additional retired proteins that may be associated with other forms of cancer.

Key Dates